News

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio’s (NASDAQ: RLYB) full interest in their joint ...
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals
Detailed price information for Rallybio Corporaton (RLYB-Q) from The Globe and Mail including charting and trades.